文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气

定义新型冠状病毒肺炎的潜在治疗靶点:单中心队列的横断面分析

Defining Potential Therapeutic Targets in Coronavirus Disease 2019: A Cross-Sectional Analysis of a Single-Center Cohort.
PubMed 文献 · Crit Care Explor · 2021-08-06
一句话结论在新冠住院患者中,白介素-6等6种生物标志物可区分轻重症,但绝对值多仅轻度升高,提示相应免疫调节治疗获益可能有限。

该研究为单中心回顾性观察队列,纳入86例新冠住院患者(轻症44例、重症42例),检测入院5天内10种细胞因子/信号蛋白、IgG抗体及中和滴度。结果显示白介素-6、白介素-7、白介素-8、干扰素-α2a、干扰素-β、白介素-1受体拮抗剂共6种标志物可区分轻重症,但多数仅轻度高于健康志愿者。轻重症患者中可检测到刺突蛋白或核衣壳蛋白IgG抗体的比例相似且水平相当,重症患者中和滴度更高。作者认为部分标志物(尤其白介素-6)可能有助于识别可从特定免疫调节治疗中获益的患者,但标志物绝对值常不能区分轻重症或死亡,提示这些免疫调节治疗获益可能有限。

要点

  • 86例新冠住院患者中,白介素-6等6种细胞因子可区分轻症与重症,但多数仅轻度高于健康志愿者。
  • 轻重症患者中可检测到刺突蛋白或核衣壳蛋白IgG抗体的比例相似,两组抗体水平相当。
  • 重症患者的中和滴度高于轻症患者。
  • 作者认为白介素-6等标志物可能有助于识别可从免疫调节治疗中获益的患者,但绝对值常不能区分轻重症或死亡。

适用人群与场景

  • 入住英国三级学术医疗中心(University College London)并确诊新型冠状病毒肺炎的患者。
  • 共86例,其中轻症44例(51%),重症42例(49%)。

研究设计与关键结果

  • 研究为单中心回顾性观察队列,检测入院5天内血清中10种细胞因子/信号蛋白(粒细胞-巨噬细胞集落刺激因子、干扰素-α2a、干扰素-β、干扰素-γ、白介素-1β、白介素-1受体拮抗剂、白介素-6、白介素-7、白介素-8、肿瘤坏死因子-α)、针对新冠病毒刺突蛋白或核衣壳蛋白的IgG抗体及抗体中和滴度。
  • 通过ClinicalTrials.gov检索到477项随机试验,涵盖168种不同疗法、83条不同通路。
  • 10种标志物中6种(白介素-6、白介素-7、白介素-8、干扰素-α2a、干扰素-β、白介素-1受体拮抗剂)可区分轻症与重症患者,但多数标志物水平与健康志愿者相似或仅轻度升高。
  • 轻症与重症患者中可检测到刺突蛋白或核衣壳蛋白IgG抗体的比例相似,两组抗体水平相当。
  • 重症患者的中和滴度高于轻症患者。

证据类型、等级与局限

  • 证据类型:单中心回顾性观察队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为部分治疗性和预后性生物标志物可能有助于识别可从特定免疫调节治疗中获益的新冠患者,尤其是白介素-6。
  • 作者指出生物标志物绝对值常不能区分轻重症或死亡,提示这些免疫调节治疗可能获益有限。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Multiple mechanisms have been proposed to explain disease severity in coronavirus disease 2019. Therapeutic approaches need to be underpinned by sound biological rationale. We evaluated whether serum levels of a range of proposed coronavirus disease 2019 therapeutic targets discriminated between patients with mild or severe disease.

DESIGN: A search of ClinicalTrials.gov identified coronavirus disease 2019 immunological drug targets. We subsequently conducted a retrospective observational cohort study investigating the association of serum biomarkers within the first 5 days of hospital admission relating to putative therapeutic biomarkers with illness severity and outcome.

SETTING: University College London, a tertiary academic medical center in the United Kingdom.

PATIENTS: Patients admitted to hospital with a diagnosis of coronavirus disease 2019.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Eighty-six patients were recruited, 44 (51%) with mild disease and 42 (49%) with severe disease. We measured levels of 10 cytokines/signaling proteins related to the most common therapeutic targets (granulocyte-macrophage colony-stimulating factor, interferon-α2a, interferon-β, interferon-γ, interleukin-1β, interleukin-1 receptor antagonist, interleukin-6, interleukin-7, interleukin-8, tumor necrosis factor-α), immunoglobulin G antibodies directed against either coronavirus disease 2019 spike protein or nucleocapsid protein, and neutralization titers of antibodies. Four-hundred seventy-seven randomized trials, including 168 different therapies against 83 different pathways, were identified. Six of the 10 markers (interleukin-6, interleukin-7, interleukin-8, interferon-α2a, interferon-β, interleukin-1 receptor antagonist) discriminated between patients with mild and severe disease, although most were similar or only modestly raised above that seen in healthy volunteers. A similar proportion of patients with mild or severe disease had detectable spike protein or nucleocapsid protein immunoglobulin G antibodies with equivalent levels between groups. Neutralization titers were higher among patients with severe disease.

CONCLUSIONS: Some therapeutic and prognostic biomarkers may be useful in identifying coronavirus disease 2019 patients who may benefit from specific immunomodulatory therapies, particularly interleukin-6. However, biomarker absolute values often did not discriminate between patients with mild and severe disease or death, implying that these immunomodulatory treatments may be of limited benefit.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Arulkumaran N, Snow TAC, Kulkarni A, et al. Defining Potential Therapeutic Targets in Coronavirus Disease 2019: A Cross-Sectional Analysis of a Single-Center Cohort. Crit Care Explor. 2021. PMID: 34386774. doi:10.1097/CCE.0000000000000488

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。